Invites Biocore인바이츠바이오코아
216400 · KONEX · ₩216400 · 인바이츠바이오코아
- Market cap
- ₩11B
- Enterprise value
- ₩38B
- P/E
- —
- P/B
- 4.0×
- Dividend yield
- 0.0%
- ROE
- −312.7%
- Net margin
- −49.9%
Trailing 12 months from filed financial statements, as of FY 2025. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−76.1% from the high
₩222Today: ₩1,195 – ₩1,394₩5,800
Returns
- 1W+1.5%
- 1M+0.9%
- 3M+106.7%
- 6M−58.1%
- YTD−69.5%
- 1Y−63.4%
- Volume today
- 161
- 0.6× the 20-day average
- Traded today
- ₩204,026
- Listed shares
- 7,711,315
- EPS (12 months)
- −₩1,077
- Earnings yield −77.5%
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Only an amended dividend filing is listed, which is routine. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat1.4% over the last month; the price is above its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Invites Biocore stock overview
Invites Biocore (인바이츠바이오코아, KRX: 216400) is listed on KONEX, in the Biotech & Pharma sector. The company is a Korean contract research organization (CRO) that supports drug development, mainly for pharmaceutical companies developing new and generic drugs. Its shares closed at ₩1,389 on Oct 30, 2026, down 0.79% on the day, giving it a market value of ₩11B.
Key facts
- Market cap
- ₩11B
- Sector
- Biotech & Pharma
- Latest price change
- −0.79%
- As of
- Oct 30, 2026
- Main business
- The company is a Korean contract research organization (CRO) that supports drug development, mainly for pharmaceutical companies developing new and generic drugs.
Quick answers about Invites Biocore
- What does Invites Biocore do?
- The company is a Korean contract research organization (CRO) that supports drug development, mainly for pharmaceutical companies developing new and generic drugs. Its core services include bioanalysis, bioequivalence and clinical trial support from early-phase trials, toxicokinetic testing, and GLP-certified analysis, with clients including domestic pharmaceutical firms and multinational partners. The company also operates a pharmaceutical quality control business and other units in cold-chain packaging and distribution.
- What is the market cap of Invites Biocore?
- The market capitalisation of Invites Biocore was ₩11B at the close on Oct 30, 2026.
- Who are the largest shareholders of Invites Biocore?
- According to the latest official filings, the largest reported holders are Invites Genomics (24.21%, as of Jan 19, 2026); SBI Investment (6.17%, as of Aug 28, 2026); SBI-Growth Ladder KONEX Activation Fund (0.90%, as of Aug 28, 2026).
- When is the next earnings report from Invites Biocore?
- Korean companies rarely announce results dates in advance. Based on when Invites Biocore filed the same report in past years, its next annual results is expected between Mar 18, 2027 and Mar 20, 2027.
Company profile
The company is a Korean contract research organization (CRO) that supports drug development, mainly for pharmaceutical companies developing new and generic drugs. Its core services include bioanalysis, bioequivalence and clinical trial support from early-phase trials, toxicokinetic testing, and GLP-certified analysis, with clients including domestic pharmaceutical firms and multinational partners. The company also operates a pharmaceutical quality control business and other units in cold-chain packaging and distribution.
Written by AI from the company's latest annual report.
- Korean name
- 인바이츠바이오코아
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 신승수
- Founded
- May 2001
- Listed
- Jun 2015
- Listed shares
- 7,711,315
- Fiscal year ends
- Month 12
- Website
- www.bio-core.com
Similar companies
- Samsung Biologics207940 · ₩69T₩1,487,000+8.86%
- Celltrion068270 · ₩44T₩191,600+1.22%
- Alteogen196170 · ₩15T₩211,500−3.86%
- SK biopharmaceuticals326030 · ₩6.1T₩77,700−0.13%
- Yuhan000100 · ₩5.5T₩75,100+0.54%
- HLB028300 · ₩5.3T₩40,000+0.76%
- Hanmi Pharm128940 · ₩5.3T₩415,000+6.82%
- SAM Chun Dang Pharm000250 · ₩4.3T₩182,700−3.13%
Recent filings
See all- Amended: Cash dividend decisionOct 29, 2026
- Investor relations (IR) eventOct 6, 2026
- Investor relations (IR) eventSep 18, 2026
- 5%+ holding reportAug 28, 2026
- 5%+ holding reportAug 28, 2026
Titles in Korean until English translations are added.
Also known as: Invites Biocore / 인바이츠바이오코아 / 216400 / KRX:216400
Source: KRX statistical information